AU2021320147B2 - Formulations of triphenyl calcilytic compounds - Google Patents

Formulations of triphenyl calcilytic compounds

Info

Publication number
AU2021320147B2
AU2021320147B2 AU2021320147A AU2021320147A AU2021320147B2 AU 2021320147 B2 AU2021320147 B2 AU 2021320147B2 AU 2021320147 A AU2021320147 A AU 2021320147A AU 2021320147 A AU2021320147 A AU 2021320147A AU 2021320147 B2 AU2021320147 B2 AU 2021320147B2
Authority
AU
Australia
Prior art keywords
weight
tablet formulation
tablet
amount
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021320147A
Other languages
English (en)
Other versions
AU2021320147A1 (en
Inventor
Ali KOMEYLI
Leena Prasad
Uma Sinha
Ananth SRIDHAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Calcilytix Therapeutics Inc
Original Assignee
Calcilytix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calcilytix Therapeutics Inc filed Critical Calcilytix Therapeutics Inc
Publication of AU2021320147A1 publication Critical patent/AU2021320147A1/en
Application granted granted Critical
Publication of AU2021320147B2 publication Critical patent/AU2021320147B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021320147A 2020-08-04 2021-08-03 Formulations of triphenyl calcilytic compounds Active AU2021320147B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063061050P 2020-08-04 2020-08-04
US63/061,050 2020-08-04
PCT/US2021/044295 WO2022031666A1 (en) 2020-08-04 2021-08-03 Formulations of triphenyl calcilytic compounds

Publications (2)

Publication Number Publication Date
AU2021320147A1 AU2021320147A1 (en) 2023-03-30
AU2021320147B2 true AU2021320147B2 (en) 2026-07-30

Family

ID=77431430

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021320147A Active AU2021320147B2 (en) 2020-08-04 2021-08-03 Formulations of triphenyl calcilytic compounds

Country Status (13)

Country Link
US (2) US20220040112A1 (enExample)
EP (1) EP4192438A1 (enExample)
JP (2) JP7827696B2 (enExample)
KR (1) KR20230106582A (enExample)
CN (1) CN116648243A (enExample)
AR (1) AR123147A1 (enExample)
AU (1) AU2021320147B2 (enExample)
BR (1) BR112023002107A2 (enExample)
CA (1) CA3188044A1 (enExample)
IL (1) IL300285A (enExample)
MX (1) MX2023001438A (enExample)
TW (1) TWI924683B (enExample)
WO (1) WO2022031666A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116648243A (zh) 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂
MX2023003129A (es) * 2020-09-18 2023-08-04 Calcilytix Therapeutics Inc Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1).
WO2024160842A1 (en) 2023-01-30 2024-08-08 Medizinische Universität Wien Use of calcilytics for preventing or treating hypoparathyroidism associated with anterior neck surgery

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304174B2 (en) * 2003-04-23 2007-12-04 Japan Tobacco Inc. CaSR antagonist

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1964548A1 (en) * 2007-03-02 2008-09-03 Novartis AG Pharmaceutical compositions comprising a calcilytic agent
SG174564A1 (en) * 2009-03-26 2011-10-28 Japan Tobacco Inc Process for producing carboxylic acid compound
ES2900353T3 (es) * 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
GB201217330D0 (en) * 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
BR112020013073A2 (pt) 2017-12-29 2020-12-01 Biomarin Pharmaceutical Inc. composto, composto, estereoisômero único ou mistura de estereoisômeros ou sal farmaceuticamente aceitável, composição farmacêutica, método de tratamento de uma doença ou distúrbio e composto ou sal farmaceuticamente aceitável do mesmo
WO2021029517A1 (en) 2019-08-13 2021-02-18 Dongguk University Industry-Academic Cooperation Foundation Pharmaceutical composition for improving or treating post-surgical hypoparathyroidism and treatment method using the same
GB201918586D0 (en) * 2019-12-17 2020-01-29 Patterson James Engineered platelets for targeted delivery of a therapeutic agent
CN116648243A (zh) 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂
MX2023003129A (es) 2020-09-18 2023-08-04 Calcilytix Therapeutics Inc Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1).

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304174B2 (en) * 2003-04-23 2007-12-04 Japan Tobacco Inc. CaSR antagonist

Also Published As

Publication number Publication date
BR112023002107A2 (pt) 2023-03-07
CN116648243A (zh) 2023-08-25
AR123147A1 (es) 2022-11-02
US12357576B2 (en) 2025-07-15
EP4192438A1 (en) 2023-06-14
MX2023001438A (es) 2023-06-15
JP7827696B2 (ja) 2026-03-10
TW202220642A (zh) 2022-06-01
US20220040112A1 (en) 2022-02-10
CA3188044A1 (en) 2022-02-10
JP2026086851A (ja) 2026-05-26
KR20230106582A (ko) 2023-07-13
IL300285A (en) 2023-04-01
JP2023536667A (ja) 2023-08-28
WO2022031666A1 (en) 2022-02-10
US20240074978A1 (en) 2024-03-07
AU2021320147A1 (en) 2023-03-30
TWI924683B (zh) 2026-05-11